Alcyone Therapeutics
Manufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
116 John St Ste 300, Lowell, Massachuset...Phone Number
(978) 709-1946Website
www.alcyonetx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Alcyone Therapeutics
Alcyone Therapeutics is a biotechnology company pioneering next-generation precision central nervous system (CNS) therapies to improve the lives of patients and families impacted by severe neurological conditions. Alcyone Therapeutics is advancing a pipeline of adeno-associated virus (AAV) gene therapy programs that leverage its proprietary, next-generation CNS delivery technology platform.Explore more
Alcyone Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Alcyone Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Alcyone Therapeutics is spiking on competitors!
Alcyone Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Alcyone Therapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Alcyone Therapeutics has new funding data
Product Launch: Get notified when Alcyone Therapeutics launches new products
Earning: See what the market has to say on Alcyone Therapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Alcyone Therapeutics
Check if Alcyone Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined Alcyone Therapeutics as Masked Content
Find 3 more new buyers
Compare Similar Companies to Alcyone Therapeutics
Compare insights from companies similar to Alcyone Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$6.3M
11-50
Private
$75M
2020
Company Profile Activity
Activity Insights
Alcyone Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Alcyone Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Alcyone Therapeutics.
Alcyone Therapeutics Tech Stack
A closer look at the technologies used by Alcyone Therapeutics
Most Recent Scoops
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Funding
Funding
Open Position
Executive Move
Executive Moves, Board of Directors
Alcyone Therapeutics News & Media
Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates
CAMBRIDGE, Mass., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the company has entered into a definitive agreement to acquire Massachusetts-based Alcyone Therapeutics. As part of an existing partnership with Alcyone Therapeutics, the companies are advancing ThecaFlex DRx™, an implantable subcutaneous port and catheter device being investigated for the intrathecal delivery of antisense oligonucleotides (ASOs). ThecaFlex DRx™ is designed to provide an alternative to repeAlcyone Therapeutics Announces Strategic Financing to Advance an Expanded Pipeline of Pediatric-Focused Precision Therapeutics for Severe Neurological Diseases
Expanded collaboration with Nationwide Children's Hospital adds new funding and a third therapeutic candidate (CLN-301) to Alcyone's diversified portfolio of precision CNS therapeutics and delivery technologies CLN-301 is a clinical-stage transformative gene therapy in development for...Alcyone Therapeutics Announces Continued Enrollment Approval from FDA of the PIERRE Pivotal IDE Clinical Study of the ThecaFlex DRx™ System for Administration of nusinersen
Alcyone's ThecaFlex is an implantable medical device under investigation for routine subcutaneous administration of therapeutics to the cerebrospinal fluid (CSF). The first stage of the pivotal IDE PIERRE trial has been completed. 10 spinal muscular atrophy (SMA) patients have undergone...Alcyone Therapeutics Appoints Dr. Norbert Riedel as Chairman of the Board and Dr. Kathrin Meyer as Chief Scientific Officer
Alcyone Therapeutics, a clinical-stage biotechnology company pioneering next-generation precision genetic therapies for complex neurological conditions, today announces appointments of Norbert Riedel,... Read More The post Alcyone Therapeutics Appoints Dr. Norbert Riedel as Chairman of the Board and Dr. Kathrin Meyer as Chief Scientific Officer appeared first on citybiz.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Alcyone Therapeutics
Sign Up For FreeTo access detailed company insights
Alcyone Therapeutics is a biotechnology company pioneering next-generation precision central nervous system (CNS) therapies to improve the lives of patients and families impacted by severe neurological conditions. Alcyone Therapeutics is advancing a pipeline of adeno-associated virus (AAV) gene therapy programs that leverage its proprietary, next-g... Read More
